Trial
NCT03217838
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
—
Condition
Acute Myeloid Leukaemia
Intervention
AZD2811
Why stopped
strategic decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-04-05